Hacettepe University Journal of the Faculty of Pharmacy, vol.42, no.1, pp.46-59, 2022 (Scopus)
© 2022, Hacettepe University, Faculty of Pharmacy. All rights reserved.Cancer is the most common type of cancer in women. Many genetic and environmental factors play an important role in breast cancer and therefore it is considered as a heterogeneous disease. Nowadays, new treatment approaches are being studied for reasons such as the different treatment responses of the defined subtypes to each other, the development of resistance to traditional therapies in clinical use, the high rate of relapse after treatment, and the damage to healthy cells by the chemotherapeutics. Current approaches in breast cancer treatment such as immunotherapy, PI3K / AKT / mTOR inhibitors, JAK / STAT inhibitors, CDK4 / 6 inhibitors target signaling pathways that play a role in breast cancer development and / or contribute to the development of resistance.